Periodic Reporting for period 2 - Klikkit (Advanced telemedicine button-based platform as a versatile solution for care organisations to manage elderly patients medication and treatment plans remotely)
Reporting period: 2021-05-01 to 2022-02-28
Along with the activities linked to WP.1 we worked on the first tasks of WP.2 namely the large-scale pilot master plan and the technology ready for deployment: (1) Defining the protocol, intervention and control group. (2) Preparing the data handling agreement for the ethical committee. (3) Defining the contractual terms for our collaboration with Caritas. (4) Preparing the system infrastructure for the pilot and the technology ready for deployment.
Our solution can be applied to any form and aspect of treatment, it is based on behavioural science principles and it is proven to uniquely nudge the elderly leading to a constant reinforcement of positive health habits :
Along with the proven increase in patient adherence of 38%, we believe that Klikkit can: (1) Decrease the number of nurse visits to patients by 60%, (2) Decrease the number of adverse events (overmedication as well as undermedication) by 75%, (3) Decrease the nurse reporting of daily tasks by 30%. (4) Decrease care utilisation due to non-compliance. (As a reference, if we consider only pharmacological compliance, the cost for per EU citizen 65+ non-compliant to medication is averaged to €1.750 a year).
Additionally, given the large number of senior citizens’ compliance data, Klikkit will aid several programs, strategies and organisations that are seeking longer and healthier lives, like CHRODIS Joint Action with the objective to help EU countries and regions exchange good practices in tackling elderly care with particular focus on long term therapies for chronic conditions. Its scalable nature to other segments, makes the Klikkit an attractive solution addressing the goals of the eHealth Action Plan 2012 - 2020, that provides a roadmap to empower elderly and healthcare workers, to link up devices and technologies, and to invest in research towards the personalised medicine of the future.